This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Kirsten Axelsen moderates the PhRMA-sponsored panel session titled “Progress or Regress…How does CMS’ Maximum Fair Price Negotiation align with patient-centered evidence assessment in health care decision-making? on HTA system learnings for CMS’ MFP process.
For more information on this event, click here.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...
